SYBLEU INC (SYBE)
USD 0.06
(34.15%)
USD 0.06
(34.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 681.41 Thousand USD | 108.81% |
| 2021 | 326.33 Thousand USD | 59.84% |
| 2020 | 204.16 Thousand USD | 1702.11% |
| 2019 | 11.32 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 687.47 Thousand USD | 0.89% |
| 2023 Q2 | 681.41 Thousand USD | 106.97% |
| 2023 Q1 | 329.22 Thousand USD | 0.66% |
| 2023 Q4 | 694.11 Thousand USD | 0.97% |
| 2022 Q4 | 327.08 Thousand USD | 94.89% |
| 2022 Q3 | 167.82 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2383.917% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 92.801% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.06% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 15.749% |
| Rebus Holdings, Inc. | 5.24 Million USD | 87.001% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.845% |
| Qrons Inc. | 1.48 Million USD | 54.228% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 44.429% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.09% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1424.55% |
| Skye Bioscience, Inc. | 14.07 Million USD | 95.158% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.722% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 92.889% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -61.638% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.638% |
| Intellipharmaceutics International Inc. | 12 Million USD | 94.326% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 82.308% |
| Mesoblast Limited | 188.44 Million USD | 99.638% |
| Marizyme, Inc. | 26.67 Million USD | 97.446% |
| Genus plc | 485 Million USD | 99.86% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 88.337% |
| Pharming Group N.V. | 244.07 Million USD | 99.721% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 66.101% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 72.92% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 82.068% |
| ContraFect Corporation | 32.53 Million USD | 97.905% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 65.608% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 82.198% |
| IMV Inc. | 37.93 Million USD | 98.204% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 94.215% |
| MultiCell Technologies, Inc. | 1617.67 USD | -42023.115% |
| ONE Bio Corp. | 27.49 Million USD | 97.522% |
| Accustem Sciences Inc. | 1.07 Million USD | 36.862% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.12% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 67.783% |
| Q BioMed Inc. | 8.13 Million USD | 91.622% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.178% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 86.758% |
| Biomind Labs Inc. | 1.49 Million USD | 54.53% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.426% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 92.464% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 96.297% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 52.477% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -379.547% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -238.816% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 88.141% |
| GB Sciences, Inc. | 5.41 Million USD | 87.422% |
| Alpha Cognition Inc. | 7.16 Million USD | 90.489% |
| HST Global, Inc. | 593.59 Thousand USD | -14.795% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 45.885% |
| Halberd Corporation | 728.71 Thousand USD | 6.492% |
| Enzolytics Inc. | 365.26 Million USD | 99.813% |
| Agentix Corp. | 2.51 Million USD | 72.858% |
| Resverlogix Corp. | 67.39 Million USD | 98.989% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 18.757% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.847% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 60.244% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.246% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 94.275% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 81.408% |
| AVAX Technologies, Inc. | 3.99 Million USD | 82.938% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2371.664% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.949% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -185.523% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 81.753% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -0.085% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 74.871% |
| Kadimastem Ltd | 3.5 Million USD | 80.558% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -918.113% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.644% |
| BioStem Technologies, Inc. | 15.9 Million USD | 95.716% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -46.635% |
| LadRx Corporation | 2.2 Million USD | 69.034% |
| Cell Source, Inc. | 15.8 Million USD | 95.689% |
| Regen BioPharma, Inc. | 5.45 Million USD | 87.514% |
| Regen BioPharma, Inc. | 5.45 Million USD | 87.514% |
| NovAccess Global Inc. | 7.86 Million USD | 91.331% |
| Affymax, Inc. | 8.87 Million USD | 92.319% |
| Itoco Inc. | 1.65 Million USD | 58.781% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 66.786% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 88.735% |
| Mobile Lads Corp. | 1.31 Million USD | 48.122% |
| CytoDyn Inc. | 127.89 Million USD | 99.467% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1530.214% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 56.498% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 93.831% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 88.833% |
| International Stem Cell Corporation | 5.27 Million USD | 87.087% |
| Bioxytran, Inc. | 3.24 Million USD | 79.03% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -8.885% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 85.242% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.338% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.94% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 66.356% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 87.561% |
| Neutra Corp. | 973.52 Thousand USD | 30.006% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.652% |
| PureTech Health plc | 125.58 Million USD | 99.457% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 81.863% |
| IXICO plc | 1.9 Million USD | 64.142% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.681% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.341% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Cellectis S.A. | 249.36 Million USD | 99.727% |